Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Double-blind, Placebo-controlled, Multicenter, Phase II/III Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With Moderate to Severe Systemic Lupus Erythematosus
Brief Summary: This is a Phase II/III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of rituximab compared with placebo when combined with a single stable background immunosuppressive medication in subjects with moderate to severe systemic lupus erythematosus (SLE). The primary efficacy endpoint of the trial will be evaluated at 52 weeks.


Options:
A: Arm Label: A-623 high dose weekly; Type: EXPERIMENTAL; Interventions: Drug: A-623 | Arm Label: A-623 low dose weekly; Type: EXPERIMENTAL; Interventions: Drug: A-623 | Arm Label: A-623 high dose every 4 weeks; Type: EXPERIMENTAL; Interventions: Drug: A-623 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo Comparator | Intervention Type: DRUG; Name: A-623; Assigned to Arm(s): A-623 high dose weekly | Intervention Type: DRUG; Name: A-623; Assigned to Arm(s): A-623 low dose weekly | Intervention Type: DRUG; Name: A-623; Assigned to Arm(s): A-623 high dose every 4 weeks | Intervention Type: OTHER; Name: Placebo Comparator; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: MEDI 545 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Biological: MEDI-545 | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Biological: MEDI-545 | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Biological: MEDI-545 | Arm Label: 5; Type: ACTIVE_COMPARATOR; Interventions: Biological: MEDI-545 | Intervention Type: BIOLOGICAL; Name: MEDI-545; Assigned to Arm(s): 2 | Intervention Type: BIOLOGICAL; Name: MEDI 545; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: MEDI-545; Assigned to Arm(s): 3 | Intervention Type: BIOLOGICAL; Name: MEDI-545; Assigned to Arm(s): 4 | Intervention Type: BIOLOGICAL; Name: MEDI-545; Assigned to Arm(s): 5
C: Arm Label: Rituximab 1000 mg + prednisone; Type: EXPERIMENTAL; Interventions: Drug: Rituximab, Drug: Prednisone, Drug: Acetaminophen, Drug: Diphenhydramine | Arm Label: Placebo + prednisone; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Prednisone, Drug: Acetaminophen, Drug: Diphenhydramine | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Rituximab 1000 mg + prednisone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + prednisone | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Placebo + prednisone, Rituximab 1000 mg + prednisone | Intervention Type: DRUG; Name: Acetaminophen; Assigned to Arm(s): Placebo + prednisone, Rituximab 1000 mg + prednisone | Intervention Type: DRUG; Name: Diphenhydramine; Assigned to Arm(s): Placebo + prednisone, Rituximab 1000 mg + prednisone
D: Arm Label: Part A, 1 mg/kg CNTO 136; Type: EXPERIMENTAL; Interventions: Drug: 1 mg/kg CNTO 136 | Arm Label: Part A, 4 mg/kg CNTO 136; Type: EXPERIMENTAL; Interventions: Drug: 4 mg/kg CNTO 136 | Arm Label: Part A, 10 mg/kg CNTO 136; Type: EXPERIMENTAL; Interventions: Drug: 10 mg/kg CNTO 136 | Arm Label: Part B, 10 mg/kg CNTO 136/placebo; Type: EXPERIMENTAL; Interventions: Drug: 10 mg/kg CNTO 136, Drug: Placebo | Intervention Type: DRUG; Name: 1 mg/kg CNTO 136; Assigned to Arm(s): Part A, 1 mg/kg CNTO 136 | Intervention Type: DRUG; Name: 4 mg/kg CNTO 136; Assigned to Arm(s): Part A, 4 mg/kg CNTO 136 | Intervention Type: DRUG; Name: 10 mg/kg CNTO 136; Assigned to Arm(s): Part A, 10 mg/kg CNTO 136, Part B, 10 mg/kg CNTO 136/placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Part B, 10 mg/kg CNTO 136/placebo

Answer: C